IBRANCE is the first CDK4/6 inhibitor to show benefit in a large Phase 3 trial in first-line HR+, HER2+ metastatic breast cancer, in combination with anti-HER2 and endocrine therapy
CLL is one of the most common leukemias among adults affecting more than 200,000 people in the US
This partnership will enable healthcare organizations to provide best-in-class patient/consumer experiences
Enhertu demonstrated clinically meaningful efficacy in previously treated patients
The partnership marks a pivotal step towards developing new therapies for combating Sickle Cell Disease
Based on ECHO Phase III trial which demonstrated Calquence combination reduced risk of disease progression or death by 27% compared to standard-of-care chemoimmunotherapy
Quinidine Sulphate helps manage rare irregular heartbeat conditions
Dupixent is indicated for the approximately 300,000 adults in the US with inadequately controlled COPD and an eosinophilic phenotype
This case is an isolated case, similar to the earlier 30 cases reported in India from July 2022 onwards
MyClad is a global Phase III study evaluating the efficacy and safety of cladribine capsules for the treatment of generalized Myasthenia Gravis (gMG)
Subscribe To Our Newsletter & Stay Updated
